Subject Index .A.ctivin, parturition and, 380 Cell cultures, endometrial, proliferation of, Adenylate cyclase, parathyroid hormone 238 stimulating, 365 Cell surface, endometrial, implantation and, Adhesion formation, pathophysiology of, 447 103 Adhesion molecules Cell-mediated immune mechanism, 235 expression of, during endometrial cycle, Cellular proliferation, cytokine regulation of, 103 322 immunological implications of, 43 Cervical canal, endometrial carcinoma and, Adjunctive progestogen, estrogen replacement 485 therapy and, 278 Cervical ripening Alkaline phosphatase, 285 preterm labor and, 415 Amniochorion, prelabor rupture of fetal RU 486 and, 402 membranes and, 430 Cervix, antiprogestins and, 399 Amniotic fluid Circulation, endometrial, 51 activin in, 381 Climacteric symptoms, 264 vasopressin in, 374 Clomiphene citrate, 193 Androgens, ovarian, 216 COi laser Antiestrogenic effect, 194 cystectomy and, 456 Antiprogestins, induction of labor and, 387 deeply infiltrating endometriosis and, 335 Apo E, trophoblast cells and, 94 Colony-stimulating factor, leukemia inhibitory Appendectomy, 434 factor and, 158 Aquadissection, 456 Colpotomy, large myomas and, 452 Arteries, uterine, innervation of, 51 Common terminal pathway of parturition, 414 Complications laparoscopy and laparotomy and, 441 Benign cystic teratoma, 455 uterine septa resection and, 473 Beta-endorphin, steroid hormones and, 245 Contraception, hormonal, 257 Biochemical ligand techniques, 27 Contraceptives, oral, 260 Biopsy, hormone replacement therapy and, Controlled ovarian hyperstimulation cycles, 263 216 Bleeding, uterine, role of PAI-1 in, 57 Corticotropin-releasing factor, parturition and, Blood flow, uterine, effects of some peptides 380 on, 52 Culdotomy incision, 457 Bowel resection, 439 Cystectomy, laparoscopic, 455 Breast cancer, adjuvant therapy for, 310 Cytokine regulation, endometriosis and, 322 Bridging ligand, bifunctional, 115 Cytokines Burch procedure, 436 development of microenvironments in human endometrium and, 1 uterine cell proliferation and implantation Ca125, deeply infiltrating endometriosis and, 158 and, 334 uterine cervix and, 403 Calcium channels, antiprogestins and, 398 Cytotrophoblasts, 166 cAMP fibronectin expression regulated by, 133 parathyroid hormone and, 368 D9BI epitope, 109 prolactin induced by, 22 l-Deamino-2-D-(OEt)-4-Thr-8-Om-oxytocin, Cancer, endometrial, hormonal production 53 and, 80 Death rates, cancer, 276 Cardiovascular disease, 19-nortestosterone Decidua, placental, vasopressin in, 375 and, 87 Decidual cells, hemostasis and menstruation Cardiovascular protection, 274 and, 58 CD44, expression of, in human endometrium, Decidual/membrane activation, preterm labor 113 and, 417 493 494 ANNALS NEW YORK ACADEMY OF SCIENCES Decidual receptors, 27 recurrence of, 358 Decidualization severe, bladder resection for, 435 ECM turnover in, 33 Endometrium (see also Human endometrium) growth factors and, 7 donor oocyte program and, 198 protease expression during, 33 ectopic, 322 stromal cells, 19, 21 eutopic, 322 Diethylstilbestrol. dual estrogenic and receptive, 143 progestagenic activities and, 286 retarded, 180 Distal pathology, laparoscopy for, 463 Endoscopic surgery, medical suppressive Donor oocyte program, 198 therapy prior to, 445 Dual estrogenic and progestagenic activities, Endoscopy, tubal evaluation and, 462 compounds with, 293 Epidermal growth factor Dynorphin, steroid hormones and, 245 decidual differentiation markers induced Dysfunctional uterine bleeding, 80 by, 8 Dysmenorrhoea, primary, spontaneous blood expression of, by cytotrophoblasts, 128 flow in, 53 leukemia inhibitory factor and, 158 Epidermal growth factor receptor, endometrial cancer histotypes and, 298 Epithelial cells, cell surface and secretory mucins in, 103 Echo pattern, endometrial, 198 Estradiol, dual estrogenic and progestagenic Echographic dendometrial patterns, tamoxifen activities and, 286 and, 314 Estrogen receptors, decidual, 26, 29 Ectopic pregnancy, 435 Estrogen replacement therapy Egg donation model, 209 cardiovascular disease and, 274 Embryo-endometrial interaction, 221 progestins and, 266-267 Embryo-epithelial stimulation, MUC-1 and, Estrogenic activities, progestagenic activities 116 and, 285 Endometrial ablation for abnormal uterine Estrogens, epidermal growth factor receptor bleeding, 469 and, 302 Endometrial cancer Extracellular matrix, decidualization and, 33 estrogen replacement therapy and, 278 Extracellular matrix protein expression, hormonal treatment and, 306 placental, 133 tamoxifen and, 310 Endometrial carcinoma epidermal growth factor receptor and, 300 hysteroscopic evaluation of, 482 Fetal membranes, 166 Endometrial contraception, 153 Endometrial differentiation, synthetic steroids activin in, 381 and, 237 vasopressin in, 374 Endometrial hyperplasia Fibronectin expression, placental, 133 estrogen replacement therapy and, 278-279 First uterine pass, 212 hormonal treatment and, 306 Endometrial maturation, embryo’s developmental stage and, 221 Endometrial preparation, adequate, 149 Clap junctions, antiprogestins and, 395 Endometrial receptivity, 193 Gemeprost, 490 Endometriosis Genit^ atrophy, estrogen replacement therapy bowel, 439 and, 272 cytokine regulation of cellular proliferation Giant mitochondria, 174 in, 322 Glucocorticoids, placental fibronectin deeply infiltrating, 333 expression by, 132 endometrioid carcinoma and, 438 Glycogen vacuole, 170 epidemiology and diagnosis of, 352 Glycosylation, MUC-1 and, 107 peritoneal, 439 Gonadotropin-releasing hormone agonist 3-D evaluation of, 342 deeply infiltrating endometriosis and, 335 prevalence of, 354 endometriosis recurrence and, 360 SUBJECT INDEX 495 hysteroscopic surgery and, 475 Hysteroscopic metroplasty, 489 medical suppression and, 445 Hysteroscopy, 479 premature luteinization and, 195 operative, ten years’ experience of, 469 tubal obstruction and, 466 tamoxifen and, 315 vascularization of endometriotic foci and, 345 Gonadotropin-releasing hormone analogs, hyperplastic endometria and, 308 Immunity, altered cellular, 43 Gonadotropins, cAMP induced by, 21 Immunocytochemistry, endometriosis and, Granulated lymphocytes, endometrial, 187 323 Granulated metrial gland cell, 188 Immunohistochemical evaluation, primary Growth factors, decidualization and, 7 endometrial carcinoma and, 299 Immunohistochemical methods, 27 Immunohistochemistry endometrial and trophoblastic tissues and, Hemostasis, endometrial, 58 222 Histologic structures, 2-D image analysis endometrial proteins and, 179 program and, 344 Immunologically mediated abortion, 235 Histological assessment, 479 Immunosuppression, 188 Histological patterns, hormone replacement Implantation therapy and, 263 donor oocyte program and, 198 Histology endometrial and embryonic factors in, 221 endometriosis and, 323 endometrial cell surface and, 103 tamoxifen and, 314 endometrial hemostasis and, 57 Histones H2A, H2B, H3, H4, 147 LDL receptor proteins and, 91 Histotype, endometrial carcinoma and, 301 leukemia inhibitory factor and, 157 H LA-DR expression of endometrial Implantation failures, intravenous epithelium, 2 immunoglobulin in prevention of, 232 HLA-G, 126 In situ hybridization, endometriosis and, 324 Hormonal and antihormonal activities, in vitro In vitro bioassays, 285 bioassays for, 285 In vitro fertilization Hormonal control, 209 donor oocyte program and, 198 Hormonal treatment, abnormal endometrial third factor hypothesis and, 215 growth and, 306 tubal infertility and, 465 Hormone antagonists, 143 In vitro influence of growth factors, 240 Hormone replacement therapy In vitro influence of physiological steroids, aspects of, 271 237 human endometrium and, 263 In vitro studies, 176 Human endometrial stromal cells, adhesion Infertility, primary unexplained, 189 molecules on, 43 Insulin-like growth factor binding protein-1, Human endometrium regulation of, 12, 15 fragments of, in vitro bioassays with, 286 Insulin-like growth factor I and II, hormone replacement therapy and, 263 proliferation of stromal cells and, 9 IFN-gamma in, 1 Integrin, 125 microenvironments in, 1 Integrins, cytotrophoblastic differentiation MUC-1 polypeptide in, 104 and, 166 Human menopausal gonadotropin, 194 intercellular adhesion molecule-1, stromal Hyperplasia, hormone replacement therapy cells and, 43 and, 268 Interferon gamma Hyperstimulation, egg donation model and, regulatory roles of, 1 209 endometriosis and, 324 Hyperstimulation regimen, donor oocyte Interleukin-1, leukemia inhibitory factor and, program and, 198 159 Hysterectomy, laparoscopic, 436 Intrauterine fetal death, RU 486 and, 394 Hysteroscopic evaluation, endometrial Intravenous immunoglobulin, implantation carcinoma and, 482 failures and, 232 4% ANNALS NEW YORK ACADEMY OF SCIENCES Ishikawa cells Maternal peripheral venous plasma, 373 dual estrogenic and progestagenic activities Matrigel, 178 in, 285 Medical suppressive therapy, rationale for use secretion of /3-endorphin and dynorphins of, 445 from, 245-246 Medrogestone, 87 Medroxyprogesterone acetate, estrogenic and progestagenic activities and, 286 ICeratan sulphate, presence of, in human Menstrual cycle, endometrial circulation endometrium. 111 during, 51 Menstruation, role of PAI-1 in, 57 Metalloproteinases, 125 ECM degradation and, 34 Labor, antiprogestins in induction of, 387 Metroplasty, hysteroscopic, 489 Lactosaminoglycans, MUC-1 and, 108 Metroplasty for uterine septa, 469 Laparoscopy Metrorrhagia, DUB and, ^ ^vantages of, over laparotomy, 453 Mice, leukemia inhibitory factor in, 158 deeply infiltrating endometriosis and, 333 Myoma endometriosis recurrence after, 359 intramural, 451 pelvic endometriosis and, 352 pedunculated, 451 peritoneal endometriosis and, 342 submucous, 474 Laparotomy Myomectomy endometriosis recurrence after, 359 hysteroscopic, 471 pelvic endometriosis and, 352 laparoscopic, operative procedure for, 450 Laser densitometric assessment, 150 laparoscopic and minilaparotomy approach Lectins, staining patterns for, 172 to, 437 Lesions Myometrial infiltration, 5-year survival rate deeply infiltrating endometriosis and, 334 and, 485 endometriotic, in pelvis, 355 Myometrial responsiveness, antiprogestins red, 343 and, 391 subtle, 342 typical, 342 white, 344 Leukemia inhibitory factor ^Jatural killer cell, 187-188 implantation and, 157 Nitric oxide system, antiprogestins and, 3% presence of, in endometrial fluids, 224 Noncontraceptive health benefits of oral Leukocytes, ectopic endometrium and, 329 contraceptives, 260 Ligand binding activities, overlapping, 91 19-Nortestosterone, cardiovascular disease Low density lipoprotein receptor family of and, 87 proteins, implantation and, 91 Nuclear channel system, 173 Luminal epithelium, 175 Nucleolar channel systems, 195 Luteal inadequacy, 149 Luteal phase diagnostics, 153 Luteinization, premature, 195 OnfFN expression in cytotrophoblasts, 133 Luteinizing hormone peak, 169 Oocyte, donor, 198 Luteinizing hormone-releasing hormone, /3- Oocytes fertilization, steps of, 226 endorphin secretion and, 250 Oophorectomy, laparoscopic, 437, 455 Lymphocyte function-related antigen-3, Opioids, endometrial, regulation of, 253 stromal cells and, 43 ORG OD14, alkaline phosphatase activity and, 289 Osteoporosis ar^^acroglobulin, trophoblast cells and, 99 estrogen replacement therapy and, 274 Macrophages, ectopic endometrium and, 329 potential risk of, 80 Mammals Ovarian cystic endometriosis, deeply lower, induction of parturition studies in, infiltrating endometriosis and, 339 390 Ovarian cysts, other endometriomas regulation of implantation in, 157 differentiated from, 356 Management of recurrent endometriosis, 360 Ovarian remnant management, 438 Marshall-Marchetti-Krantz procedure, 436 Oxytocin receptors, antiprogestins and, 3% SUBJECT INDEX 497 Proopiomelanocortin probe, 249 PaI-1, trophoblast cells and, 94 Prostaglandin Ei, decidualization process and, Parathyroid hormone-related protein, 365 24 Parturition Prostaglandin synthesis, parturition and, 381 activin and CRF in, 380 Prostaglandins common terminal pathway of, 414 bioavailability of, 418 vasopressin and, 372 uterine, effects of antiprogestins on, 394 Peptides, effects of, on human uterine blood uterine cervix and. 403 flow, 52 Protease expression, 33 Peritoneal fluid, deeply infiltrating Protein patterns, 143 endometriosis and, 334 Psychological symptoms, estrogen Placenta replacement therapy and, 272 activin and. 381 fibronectin expression in, 133 Placentation, LDL receptor proteins and, 91 ^^uality of life, estrogen replacement Plasma estradiol/progesterone ratio, 212 therapy and, 272 Plasminogen activator inhibitor type 1, endometrial hemostasis and, 61 Plasminogen activators, ECM degradation and, 34 1V2323 (gestrinone), progestagenic effects of, Polarized cells, 177 293 Polymorphic mucin MUC-1, 103 RAP, trophoblast cells and, 97 Polyps, tamoxifen and, 314 Rat uterine explants, MUC-1 and, 108 Population explosion control, 259 Recanalization, tubal, 465 Pouch of Douglas, 334 Receptivity, endometrial, hormonal control of, myomectomy and, 452 209 PP14, deeply infiltrating endometriosis and, Relaxin, decidualization process and, 24 334 Resection of submucous myomas, 469 Preeclampsia, 126 Resectoscope, 491 Pregnancy rate, donor oocyte program and, RU 486 (mifepristone), 152 198 j8-endorphin secretion and, 250 Prelabor rupture of fetal membranes, 430 cervical ripening with, 402 Presacral neurectomy, 439 chemical structure of, 389 Preterm birth, 430 concentration-dependent antagonistic effects Pretenn labor syndrome, 414 of, 291 Prevical instrument, 145 Primates, nonhuman, induction of parturition with antiprogestins in, 391 Sacral colpopexy, 440 Prodynorphin probe, 249 Second-trimester pregnancy termination, 393 Progestagenic activities, estrogenic activities Secretion and, 285 delayed, 144 Progesterone human endometrial, 143 donor oocyte program and, 198 Septate uterus, 488 dual estrogenic and progestagenic activities Shared oocyte program, 198 and, 286 Sialoglycan epitope, D9B1 and, 109 first uterine pass and, 212 Spontaneous abortion, 190 pregnancy maintenance and, 404 Squamous metaplasia, 303 production of, 80 Steric hindrance, MUC-1 and, 115 Progesterone antagonists, 144 Steroids Progesterone receptors, decidual, 26, 29 ovarian Progestins endometrial circulation during menstrual endometrial stromal cells and, 23 cycle and, 51 estrogen replacement therapy and, 266 protease expression and, 35 Progestogens, addition of, caution against, 87 synthetic, regulation of endometrial Prolactin, cAMP and, 22 differentiation by, 237 Prolactin secretion, regulation of, by IGFs, Stromal cell cultures 13, 15 metaUoproteinase expression in, 37 Proliferation, extent of, 2 plasminogen expression in, 36 498 ANNALS NEW YORK ACADEMY OF SCIENCES Stromal cells, parathyroid hormone and, 366 Stromal cells decidualization, mechanism of, Ultrasound, 479 19, 21 Ultrastructure, 172 Survival, endometrial carcinoma and, 483-484 UMR-106 cells, parathyroid hormone and, 367 Ureteroureterostomy, 440 T Urokinase, trophoblast cells and, 94 cell receptor, 186 Urokinase type-plasminogen activator, T cells, ectopic endometrium and, 329 seminal fluid samples and, 225 T lymphocytes, endometrial, 185 Uterine contractility, 415 T47D cells, dual estrogenic and progestagenic Uterine fluid, modulating embryo growth and, activities in, 285 227 Tamoxifen Uterine secretion electrophoretic (USE) eflfect of, on the endometrium, 307 patterns, assessment of, 149 endometrial cancer and, 310 Uterine secretion proteins, 145 Thickness, endometrial Uterine tissue, ligands for LDL receptor donor oocyte program and, 198 family produced by, 99 tamoxifen and, 314 Uterus, septate, 488 Third factor hypothesis, 216 Three-dimensional architecture of endometriosis, 346 ^^aginal cytodiagnosis, tamoxifen and, 313 Tissue factor, endometrial hemostasis and, 58 Variable number tandem repeat (VNTR) Tissues, endometrial and trophoblastic, 222 domain, structure of MUC-1 and, 104 Toxicity, tamoxifen, 318 Vascularization, morphometric study of, 344 Transcervical tuboscopy, 464 Vasculature, arterial and capillary, of the Transcriptional regulation, MUC-1 and, 105 human uterus, 48 Transfimbria tuboscopy, 464 Vasomotor symptoms, 271 Transforming growth factor /31, 222 Vasopressin, parturition and, 372 Transvaginal administration of progesterone, 212 Transvaginal ultrasound, tamoxifen and, 313 Zk 98299 (onapristone) Trophectoderm, 117 chemical structure of, 389 Trophoblast cells, LDL receptor family and, concentration-dependent antagonistic effects 94 of, 291 Tubal infertility, therapeutic strategy in, 460 Zoladex, suppression of ovarian activity Two-dimensional image analysis program, 344 obtained with, 87 Index of Contributors Aguzzoli, L., 380-386 De Placido, G., 232-234 Ajossa, S., 352-357 De Vita, D., 380-386 Akerlund, M., 47-56 De Ziegler, D., 209-220 Amadori, A., 298-305 Dey, T. D., 322-332 Angiolucci, M., 352-357 Di Carlo, C., 380-386 Aplin, J. D., 103-121 Di Nola, G., 358-364 Audibert, F., 460-468 Donnez, J., 342-351 Dubuisson, J-B., 450-454 Baracchini, P., 263-270 Bargelli, G., 482-487 Erk, A., 365-371 Bass, K. E., 122-131 Behzad, F., 103-121 Beier, H. M., 143-156 Fanchin, R., 209-220 Beier-Hellwig, K., 143-156 Fedele, L., 358-364 Bell, S. C., 166-168, 430-432 Ferraiolo, A., 263-270 Bergeron, C., 209-220 Ferrari, A., 380-386 Bevini, M., 479-481 Feygin, N., 33-42 Bianchi, S., 358-364 Filoni, M., 488-492 Biglia, N., 310-321 Fisher, S. J., 122-131 Birkenfeld, A., 193-197 Flamigni, C., xi, 80-90, 235-236, 479-481 Bonn, B., 143-156 Florio, P., 380-386 Borri, P., 26-32 Frydman, R., 209-220 Bouchard, P., 209-220 Bovicelli, A., 488-492 Gabrielli, S., 479-481 Branconi, F., 26-32 Gavels, M. E., 91-102 Bulletti, C., xi, 80-90, 221-231, 235-236 Galasso, M., 414-429 Bulmer, J. N., 185-192 Gallinelli, A., 380-386 Busacca, M., 43-46, 358-364 Garfield, R. E., 387-413 Buttram, V. C., Jr., 445-449 Gavi, B., 33-42 Bygdeman, M., 143-156 Gemzell-Danielsson, K., 143-156 Genazzani, A. D., 380-386 Caffiero, A., 352-357 Gerbaldo, D., 263-270 Campbell, S., 103-121 Giacomucci, E., 80-90, 235-236 Candiani, M., 358-364 Giai, M., 310-321 Cappiello, F., 232-234 Giudice, L. C., 7-18 Casanas-Roux, F., 342-351 Gomez, R., 414-429 Casey, M. L., 365-371 Graham, R. A., 103-121 Ceccarelli, C., 298-305 Gravanis, A., 245-256 Chapron, C., 450-454 Gubbini, G., 488-492 Check, J. H., 198-208 Guerriero, S., 352-357 Chianchiano, N., 469-478 Guller, S., 19-25, 132-142 Chwalisz, K., 387-413 Gurpide, E., xi, 19-25, 285-297 Colacurci, N., 232-234 Coukos, G., 91-102 Hausknecht, V., 33-42, 57-79 Coutifaris, C., 91-102 Hey, N. A., 103-121 Cristoforoni, P., 263-270, 469-478 Hill, C. J., 169-184 Cudemo, V., 33-42 Hilmes, U., 143-156 D Holinka, C. F., 257-262, 271-284 ’Hooghe, T., 333-341 De Cecco, L., 263-270 Irwin, J. C., 7-18 De Grandis, T., 310-321 De Las Fuentes, L., 7-18 de Micheroux, A. A., 380-386 Jasonni, V. M., 298-305, 479-481 499 500 ANNALS NEW YORK ACADEMY OF SCIENCES K. Parmeggiani, R., 221-231 kerenyi, T., 57-79 Pergola, G. M., 322-332 Kiesel, L., 237-244 Perino, A., 469-478 Klein, N. A., 322-332 Periti, E., 26-32 Koninckx, P. R., 333-341 Petraglia, F., 380-386 Krikun, G., 33-42, 57-79 Piccione, E., 372-379 Piras, B., 352-357 Leibman, M. I., 132-142 Polli, V., 80-90, 221-231, 235-236 Li, T. C., 169-184 Possati, G., 479-481 Licastro, F., 221-231 Prefetto, R. A., 80-90 Lockwood, C. J., 33-42, 57-79, 132-142 Pulcheri, E., 263-270 Lopez de la Osa Gonzalez, E., 306-309 M, Rece morgida, V., 263-270 lacDonald, P. C., 365-371 Romero, R., 414-429 Magri, B., 43-46 Rosati, M., 455-459 Mais, V., 352-357 Makrigiannakis, A., 245-256 Santini, D., 298-305 Malak, T. M., 166-168, 430-432 Saravelos, H., 169-184 Mappes, M., 237-244 Scarselli, G., 26-32, 482-487 Marabini, A., 488-492 Schatz, F., 33-42, 57-79 Margioris, A. N., 245-256 Schenken, R. S., 322-332 Markiewicz, L., 33-42, 57-79, 285-297 Seif, M. W., 103-121 Massonneau, M., 209-220 Sherer, D. M., 414-429 Matsuo, H., 91-102 Sismondi, P., 310-321 Mauri, A., 372-379 Stagnozzi, R., 488-492 Mazor, M., 414-429 Stefanetti, M., 488-492 Mazzone, S., 479-481 Sterzik, K., 143-156 McMaster, M. T., 122-131 Stewart, C. L., 157-165 Melis, G. B., 352-357 Stournaras, C., 245-256 Messeri, G., 26-32 Strauss, J. F. Ill, 91-102 Meuleman, C., 333-341 Strickland, D. K., 91-102 Mollo, A., 232-234 Moncini, D., 482-487 Montoya, 1. A., 322-332 Tabibzadeh, S., 1-6 Mulholland, G., 430-432 Taddei, G. L., 26-32, 482-487 Munoz, H., 414-429 Tang, B., 19-25 Muserra, G., 479-481 Tantini, C., 482-487 Tekmal, R. R., 322-332 Na Ticconi, C., 372-379 laldi, S., 298-305, 479-481 Torricelli, F., 26-32 Nazzaro, A., 232-234 Toth-Pal, E., 33-42, 57-79 Nezhat, Camran, 433-444 Tozzi, P., 26-32 Nezhat, Ceana, 433-444 Nezhat, F., 433-444 Nisolle, M., 342-351 igano, P., 43-46 Nod, L, 26-32 Vignali, M., 43-46, 358-364 Nutini, L., 26-32 Volpe, A., 372-379 Volpi, E., 310-321 O osterlynck, D., 333-341 Wa ang, E-Y., 33-42, 57-79 Mr aglierani, M., 26-32 Warren, M. A., 169-184 Palumbo, G., 232-234 Wittmaack, F., 91-102 Paoletti, A. M., 352-357 Wozniak, R., 132-142 Papp, C., 33-42, 57-79 Papp, Z., 33-42, 57-79 Zhou, X., 57-79 Pareschi, A., 479-481 Zullo, F., 232-234